Menu
Recruiting NCT06970925

Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery

Early Phase I Interventional Cardiac Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Sucrosomial Iron (SI).
Who it may be relevant to
Registry conditions: Cardiac Surgery. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Pilot Study Evaluating Efficacy and Economic Advantage of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care in Patients After Cardiac Surgery

Overview

Primary objective: to evaluate the non-inferiority in terms of improvement of hemoglobin (Hg) levels within 30 days postoperatively between two proposed treatments. Secondary objective: to evaluate the financial costs associated with Sucrosomial® Iron treatment compared to Iron Sucrose (IV), while demonstrating non-inferiority in the improvement of hemoglobin levels, reduction in transfusion requirements, and reduction of hospital/ICU stay length

Interventions

  • Dietary supplement Sucrosomial Iron (SI)
    The Sucrosomial Iron (SI) you may receive is a considered a supplement, so it has not been approved by the U.S. Food \& Drug Administration (FDA) for sale. However, it is available for over-the-counter purchase. Sucrosomial Iron (SI) has been developed by PharmaNutra.

Primary outcome measures

  • Change in hemoglobin levels [Time frame: 30 days]
  • Financial Cost [Time frame: 30 Days]
Secondary outcome measures (2)
  • Transfusion requirements [Time frame: 30 Days]
  • Length of Stay [Time frame: 30 Days]

Eligibility criteria

Inclusion criteria

  • ICU hospitalized patients who underwent non-emergent cardiac surgery
  • Post operative iron deficient or anemic patients (Hb< 12 for both men and women).
  • Patients following the same pre-operative protocol
  • Age >18 years

Exclusion criteria

  • Post operative day 1 Hg <9
  • Age >90 years
  • Patients with cancer or other chronic conditions that impair erythropoiesis (e.g. MDS)
  • Stage 3, 4 renal disease
  • Intraoperative transfusion of PRBC

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Englewood Hospital — Englewood

Identifiers

NCT: NCT06970925 · E-25-119

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗